drugset / Trial / NCT03174171
Open-label Study on Treatment of Primary Aldosteronism With Everolimus
NaSingle-groupOpen-labelTreatment
Summary
The overall objective is to evaluate everolimus as an aldosterone-lowering drug in the treatment of primary hyperaldosteronism.
Timeline
- Start
- 2017-05-22
- Primary completion
- 2018-06-25
- Completion
- 2018-06-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | 0.75 mg | Oral |